Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,217
  • Shares Outstanding, K 4,589
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -71,060 K
  • EBIT $ -54 M
  • EBITDA $ -49 M
  • 60-Month Beta 2.69
  • Price/Sales 7.13
  • Price/Cash Flow N/A
  • Price/Book 1.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -4.20
  • Growth Rate Est. (year over year) +23,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +90.87%
on 11/25/24
16.94 -76.56%
on 12/02/24
+1.85 (+87.26%)
since 11/20/24
3-Month
2.00 +98.50%
on 10/14/24
16.94 -76.56%
on 12/02/24
+0.82 (+26.03%)
since 09/20/24
52-Week
1.52 +161.17%
on 08/07/24
16.94 -76.56%
on 12/02/24
-0.22 (-5.23%)
since 12/20/23

Most Recent Stories

More News
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

SNTI : 3.97 (-0.25%)
Senti Biosciences Announces New Employment Inducement Grants

SNTI : 3.97 (-0.25%)
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study

Senti Biosciences, Inc. SNTI announced positive initial data from a phase I study that evaluated its chimeric antigen receptor natural killer (CAR-NK) cell therapy candidate, SENTI-202, for the treatment...

IMCR : 28.33 (-0.33%)
SNTI : 3.97 (-0.25%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
Senti Biosciences Reports Positive Initial clinical Results for SENTI-202 in Phase 1 Trial for Relapsed/Refractory AML

Two out of three patients achieved complete remission in a clinical trial for a novel AML cell therapy.Quiver AI SummarySenti Biosciences, Inc. announced positive early results from its Phase 1 clinical...

SNTI : 3.97 (-0.25%)
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed

The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.

SNTI : 3.97 (-0.25%)
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

SNTI : 3.97 (-0.25%)
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

SNTI : 3.97 (-0.25%)
Senti Bio Appoints Fran Schulz to Board of Directors

SNTI : 3.97 (-0.25%)
Senti Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Clinical Updates

Senti Bio reports Q3 2024 financial results, highlighting clinical progress for SENTI-202 and grant funding from CIRM.Quiver AI SummarySenti Biosciences, Inc. announced its third-quarter 2024 financial...

SNTI : 3.97 (-0.25%)
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

SNTI : 3.97 (-0.25%)

Business Summary

Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 4.70
2nd Resistance Point 4.50
1st Resistance Point 4.23
Last Price 3.97
1st Support Level 3.76
2nd Support Level 3.56
3rd Support Level 3.29

See More

52-Week High 16.94
Fibonacci 61.8% 11.05
Fibonacci 50% 9.23
Fibonacci 38.2% 7.41
Last Price 3.97
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar